Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma

Bengt Tholandera Department of Oncology, Uppsala University Hospital, Uppsala, Sweden;b Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, SwedenCorrespondence[email protected]

Anthoula Koliadia Department of Oncology, Uppsala University Hospital, Uppsala, Sweden;b Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden

Johan Botlingb Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden

Hanna Dahlstranda Department of Oncology, Uppsala University Hospital, Uppsala, Sweden;b Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden

Anne Von Heidemana Department of Oncology, Uppsala University Hospital, Uppsala, Sweden;b Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden

Håkan Ahlströmc Department of Surgical Sciences, Uppsala Sweden, Division of Radiology, Uppsala University Hospital, Uppsala, Sweden

Kjell Öbergd Department of Oncologic Endocrinology, Uppsala University Hospital, Uppsala, Sweden;e Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Gustav J. Ullenhaga Department of Oncology, Uppsala University Hospital, Uppsala, Sweden;b Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden

show all

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (6)

Tibor A. Zwimpfer, Ori Tal, Franziska Geissler, Ricardo Coelho, Natalie Rimmer, Francis Jacob & Viola Heinzelmann-Schwarz. (2023) Low grade serous ovarian cancer – A rare disease with increasing therapeutic options. Cancer Treatment Reviews 112, pages 102497.
Crossref

Marta Llaurado Fernandez, E. Marielle Hijmans, Annemiek M.C. Gennissen, Nelson K.Y. Wong, Shang Li, G. Bea A. Wisman, Aleksandra Hamilton, Joshua Hoenisch, Amy Dawson, Cheng-Han Lee, Madison Bittner, Hannah Kim, Gabriel E. DiMattia, Christianne A.R. Lok, Cor Lieftink, Roderick L. Beijersbergen, Steven de Jong, Mark S. Carey, René Bernards & Katrien Berns. (2022) NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition. Molecular Cancer Therapeutics 21:12, pages 1862-1874.
Crossref

C. Blake Gilks, Christina I. Selinger, Ben Davidson, Martin Köbel, Jonathan A. Ledermann, Diana Lim, Anais Malpica, Yoshiki Mikami, Naveena Singh, Radhika Srinivasan, Russell Vang, Sigurd F. Lax & W. Glenn McCluggage. (2022) Data Set for the Reporting of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR). International Journal of Gynecological Pathology 41:Supplement 1, pages S119-S142.
Crossref

Shan Zhu, Chunliu Zhang, Dongyan Cao, Jing Bai, Shuangni Yu, Jie Chen, Jing Wang, Tong Ren, Jiaxin Yang, Mei Yu, Xiao Xiao, Yuhua Gong, Yanfang Guan, Peiling Li, Ying Yue, Rutie Yin, Yongjun Wang, Ruifang An, Ge Lou, Jianlin Yuan, Guonan Zhang, Xuefeng Xia, Ling Yang & Yang Xiang. (2022) Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes. Oncogene 41:22, pages 3093-3103.
Crossref

Bárbara Lima, Miguel Henriques Abreu, Susana Sousa, Carla Bartosch & Deolinda Pereira. (2022) Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation. Gynecologic Oncology Reports 40, pages 100942.
Crossref

. (2021) Multiple drugs. Reactions Weekly 1882:1, pages 359-359.
Crossref

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma

Articles from other publishers (6)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma

Citations (6)

Articles from other publishers (6)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date